IGF-1 and IGFBP-1 as Possible Predictors of Response to Lifestyle Intervention-Results from Randomized Controlled Trials.

Stefan Kabisch, Nina M T Meyer, Caroline Honsek, Margrit Kemper, Christiana Gerbracht, Ayman M Arafat, Ulrike Dambeck, Martin A Osterhoff, Andreas F H Pfeiffer, Peter E H Schwarz, Jürgen Machann, Andreas L Birkenfeld, Martin O Weickert

Journal: International journal of molecular sciences 2024;25(12):

PMID: 38928106

Free Full Text on MDPI View on PubMed

Abstract

Lifestyle interventions can prevent type 2 diabetes (T2DM). However, some individuals do not experience anticipated improvements despite weight loss. Biomarkers to identify such individuals at early stages are lacking. Insulin-like growth factor 1 (IGF- 1) and Insulin-like growth factor binding protein 1(IGFBP-1) were shown to predict T2DM onset in prediabetes. We assessed whether these markers also predict the success of lifestyle interventions, thereby possibly guiding personalized strategies. We analyzed the fasting serum levels of IGF-1, IGFBP-1, and Insulin-like growth factor binding protein 2 (IGFBP-2) in relation to changes in metabolic and anthropometric parameters, including intrahepatic lipids (IHLs) and visceral adipose tissue (VAT) volume, measured by magnetic resonance imaging (MRI), in 345 participants with a high risk for prediabetes (54% female; aged 36-80 years). Participants were enrolled in three randomized dietary intervention trials and assessed both at baseline and one year post-intervention. Statistical analyses were performed using IBM SPSS Statistics (version 28), and significance was set at < 0.05. Within the 1-year intervention, overall significant improvements were observed. Stratifying individuals by baseline IGF-1 and IGFBP-1 percentiles revealed significant differences: higher IGF-1 levels were associated with more favorable changes compared to lower levels, especially in VAT and IHL. Lower baseline IGFBP-1 levels were associated with greater improvements, especially in IHL and 2 h glucose. Higher bioactive IGF-1 levels might predict better metabolic outcomes following lifestyle interventions in prediabetes, potentially serving as biomarkers for personalized interventions.

Address: Department of Endocrinology and Metabolism (Diabetes and Nutritional Medicine), Charité Universitätsmedizin Berlin, 10117 Berlin, Germany.; German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany.; Department of Clinical Nutrition/DZD, German Institute of Human Nutrition Potsdam-Rehbruecke, 14558 Nuthetal, Germany.; Department of Clinical Nutrition/DZD, German Institute of Human Nutrition Potsdam-Rehbruecke, 14558 Nuthetal, Germany.; German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany.; Department of Clinical Nutrition/DZD, German Institute of Human Nutrition Potsdam-Rehbruecke, 14558 Nuthetal, Germany.; Department of Endocrinology and Metabolism (Diabetes and Nutritional Medicine), Charité Universitätsmedizin Berlin, 10117 Berlin, Germany.; German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany.; Institute of Diabetes Research and Metabolic Diseases (IDM), Helmholtz Center Munich, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany.; Department of Internal Medicine IV-Endocrinology, Diabetology, and Nephrology, University Hospital Tübingen, 72076 Tübingen, Germany.; Department of Diabetes, School of Life Course Science and Medicine, King's College London, London WC2R 2LS, UK.; German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany.; Department for Prevention and Care of Diabetes, Clinic of Medicine III, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.; Paul Langerhans Institute Dresden, Helmholtz Center Munich, Faculty of Medicine, Technische Universität Dresden, 01307 Dresden, Germany.; German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany.; Institute of Diabetes Research and Metabolic Diseases (IDM), Helmholtz Center Munich, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany.; Section on Experimental Radiology, Department of Diagnostic and Interventional Radiology, University Hospital Tübingen, 72076 Tübingen, Germany.; Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism, University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK.; The ARDEN NET Centre, ENETS CoE, University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK.; Centre of Applied Biological & Exercise Sciences (ABES), Faculty of Health & Life Sciences, Coventry University, Coventry CV1 5FB, UK.; Translational & Experimental Medicine, Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.

DOI: 10.3390/ijms25126400

Link outs

Free resources

Full Text Sources:

Medical:

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-2677

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-OTUB1-1

MeSH Terms: Humans, Female, Male, Insulin-Like Growth Factor Binding Protein 1, Middle Aged, Insulin-Like Growth Factor I, Aged, Adult, Life Style, Diabetes Mellitus, Type 2, Biomarkers, Aged, 80 and over, Prediabetic State, Intra-Abdominal Fat, Insulin-Like Growth Factor Binding Protein 2